Blood and thinking: The identification of early Alzheimer’s disease with cognition and biochemistry

Join us for the first  Healthy Brain and Mind Research Centre webinar for 2022, presented by Professor Paul Maruff.



09 June 2022

5 – 6pm (AEST) and 8 – 9am (BST)


About the presenter:

Professor Paul Maruff PhD is Chief Innovation Officer at Cogstate Ltd, Australia. He holds appointments as Professor in Neuroscience at the Florey Institute of Neuroscience and Mental Health, and Professor in Psychology at Monash University in Melbourne, Australia. Professor Maruff received his PhD in Behavioral Sciences in 1993 from LaTrobe University in Melbourne. He continued his research in the neuropsychology of neuropsychiatric diseases in collaborations with the Institute for Cognitive and Decision Sciences at the University of Oregon and the National Institutes of Health (NIH) in the US under a fellowship from the Australian National Health and Medical Research Council (NHMRC) in 1993. Following his return to Australia, he held appointments as a Senior Lecturer in Biophysical Sciences at Swinburne University, Melbourne, and Associate Professor in Psychology at LaTrobe University. He has held continuous research grants from either the NHMRC or the Australian Research Council (ARC).

In 1998, Professor Maruff co-founded Cogstate Ltd: a company that develops cognitive tests specifically for use guiding decision-making in clinical trials and clinical practice. He has published many research articles in international peer-reviewed journals and serves on national and international advisory panels on cognitive disorders in dementia, HIV infection, psychiatric illness, oncology and sports concussion. He currently sits on the senior management committee of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of Alzheimer’s disease and is co-chair of the clinical working group of that study.

As Chief Innovation Officer at Cogstate, Professor Maruff consults to pharmaceutical companies on issues related to the use, design, implementation and analyses of cognitive assessments in more than 400 clinical, pharmaceutical-industry sponsored trials at all stages of drug development. In this role, he has been involved in the development and approval of 13 new drugs that affect cognition, including most recently esketamine for treatment-resistant depression.


Professor Maruff will discuss progress in the identification and treatment of early Alzheimer’s disease. He will consider what our role is in neuropsychology, now and in the future, as understanding of the biochemistry of the disease becomes more sophisticated and widespread.

Register now

Have a question?

We're available 9am–5pm AEDT,
Monday to Friday

If you’ve got a question, our AskACU team has you covered. You can search FAQs, text us, email, live chat, call – whatever works for you.

Live chat with us now

Chat to our team for real-time
answers to your questions.

Launch live chat

Visit our FAQs page

Find answers to some commonly
asked questions.

See our FAQs